The claim is specifically resistance to degradation in gastric juice, supported structurally by its proline content. It is not a claim of indefinite or universal stability.

Does gastric stability mean it works orally?

No. Surviving the stomach is one of three barriers; intestinal proteases and epithelial permeability are the others.

Does it still need cold storage?

Yes. Enzymatic stability says nothing about chemical hydrolysis, which is why lyophilised material is stored cold and dry.

Is BPC-157 Actually a Stable Peptide?

The short answer

The claim is specifically about resistance to degradation in human gastric juice, an environment that destroys most peptides within minutes. Its proline content gives a plausible structural basis. It does not mean the peptide is indefinitely stable in solution or resistant to all proteases.

Key facts

The claim: Stable in human gastric juice
Structural basis: Four prolines, three consecutive
Why proline helps: Proline-adjacent bonds resist most proteases
Does not mean: Indefinite solution stability
Does not mean: Resistance to every protease
Still applies: Chemical hydrolysis over time

What kind of stability is being claimed

Enzymatic and acidic stability in a specific environment. Gastric juice combines a pH around 1.5 to 3.5 with pepsin, and most peptides do not survive it. The claim is that BPC-157 does, which is a narrow and testable proposition rather than a general assertion of robustness.

Why the structure makes it plausible

Proteases require an extended backbone conformation at their active site, and proline prevents the backbone adopting it nearby. BPC-157 has four prolines including a run of three, which places a substantial fraction of its bonds in protease-resistant contexts. This is the same principle that Semax and Selank exploit with their Pro-Gly-Pro extensions, applied more extensively.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £15.99

What the claim does not cover

Chemical hydrolysis, which proceeds without enzymes and is why lyophilised storage matters. Oxidation, though the absence of cysteine and methionine largely removes that route here. And stability in other environments: resistance to pepsin at low pH does not predict resistance to a different protease in a different compartment.

Why it does not follow that oral administration works

This inference is commonly made and it does not hold. Surviving the stomach is one of three barriers to oral bioavailability. The others are enzymatic degradation in the small intestine by trypsin and chymotrypsin, and crossing the intestinal epithelium; a large, polar, charged fifteen-residue peptide is not a promising candidate for passive permeation. Gastric stability addresses the first barrier only.

Whose claim it is

The stability characterisation comes from the Zagreb group, along with most of the compound's literature. As with everything else in this category, that concentration means the finding is less independently established than its frequency of repetition suggests.

Frequently asked questions

Is BPC-157 stable?: The claim is specifically resistance to degradation in gastric juice, supported structurally by its proline content. It is not a claim of indefinite or universal stability.
Does gastric stability mean it works orally?: No. Surviving the stomach is one of three barriers; intestinal proteases and epithelial permeability are the others.
Does it still need cold storage?: Yes. Enzymatic stability says nothing about chemical hydrolysis, which is why lyophilised material is stored cold and dry.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it. Different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

The Stability Claim, Examined